Hospital
Appalachian Regional Healthcare, INC.
Appalachian Regional Healthcare, INC. was paid $33.42M by Medicaid between Jan 2018 and Dec 2024, across 261 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoAPPALACHIAN REGIONAL HEALTHCARE, INC.
WHITESBURG, KY 41858
WHITESBURG, KY 41858
33aNPI1194723726assigned 07/08/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$33.42M
24GClaims638,583
24DCodes billed261
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#21 of 36
Median peer was paid$36.08M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 100,195 | $4.79M | |
| 2019 | 84,734 | $4.75M | |
| 2020 | 90,450 | $4.30M | |
| 2021 | 101,488 | $4.72M | |
| 2022 | 90,395 | $4.53M | |
| 2023 | 94,020 | $5.33M | |
| 2024incomplete | 77,301 | $5.00M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 19,040 | 15,357 | $6.97M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 8.9% | 4,898 | 4,309 | $2.97M |
| G0378 | Hospital observation service, per hour | 5.4% | 6,571 | 3,509 | $1.81M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.0% | 4,477 | 2,952 | $1.68M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.0% | 16,638 | 14,591 | $1.68M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.6% | 3,266 | 2,757 | $1.21M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 1,712 | 1,418 | $1.20M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 4,404 | 3,618 | $1.04M |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 2.3% | 1,630 | 1,406 | $774K |
| 80053 | Comprehensive metabolic panel | 2.3% | 36,673 | 25,964 | $755K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 7,335 | 4,650 | $577K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.7% | 1,767 | 1,064 | $569K |
249 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 12,268 | $513K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.5% | 1,203 | $498K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 39,396 | $450K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 6,828 | $440K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.3% | 32,979 | $427K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 7,976 | $375K |
| 71045 | Radiologic examination, chest; single view | 1.0% | 8,929 | $339K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,880 | $324K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,756 | $309K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 8,596 | $268K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,793 | $259K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,956 | $257K |
| 84484 | <1% | 8,438 | $249K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 734 | $238K |
| 87631 | <1% | 2,722 | $224K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,730 | $223K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,812 | $215K |
| 36415 | Collection of venous blood by venipuncture | <1% | 82,285 | $204K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,995 | $198K |
| 72131 | <1% | 567 | $193K | |
| 87040 | <1% | 4,502 | $188K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,313 | $182K |
| 71250 | <1% | 662 | $160K | |
| 81001 | <1% | 18,970 | $152K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 328 | $149K |
| 73562 | <1% | 1,764 | $144K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 503 | $137K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 884 | $137K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 21,449 | $129K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,712 | $125K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,550 | $123K |
| 81025 | <1% | 5,989 | $123K | |
| 82607 | <1% | 4,075 | $123K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,918 | $119K |
| 80061 | Lipid panel | <1% | 6,495 | $112K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,976 | $103K |
| 93971 | <1% | 950 | $97K | |
| 83735 | <1% | 11,875 | $96K | |
| 83690 | <1% | 5,374 | $92K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 901 | $90K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,478 | $89K |
| 96376 | <1% | 2,782 | $82K | |
| 83880 | <1% | 2,380 | $80K | |
| 74022 | <1% | 926 | $80K | |
| 72141 | <1% | 179 | $79K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,503 | $78K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,865 | $78K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,963 | $76K |
| 73610 | <1% | 1,485 | $76K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,448 | $75K |
| 73630 | <1% | 1,479 | $72K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 273 | $70K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,449 | $67K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,349 | $66K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,526 | $66K |
| 73030 | <1% | 1,488 | $62K | |
| 93041 | <1% | 3,246 | $61K | |
| 82553 | <1% | 2,721 | $59K | |
| 73130 | <1% | 1,150 | $57K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,831 | $56K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,787 | $56K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,816 | $54K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 134 | $54K |
| 74246 | <1% | 350 | $52K | |
| 72110 | <1% | 697 | $51K | |
| 93017 | <1% | 644 | $50K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 517 | $50K |
| 84145 | <1% | 946 | $50K | |
| 82550 | <1% | 3,991 | $50K | |
| 49320 | <1% | 40 | $45K | |
| 73110 | <1% | 799 | $44K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,909 | $43K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 81 | $41K |
| 82728 | <1% | 1,220 | $36K | |
| 84703 | <1% | 2,267 | $35K | |
| 87077 | <1% | 2,784 | $35K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,041 | $34K |
| 83605 | <1% | 3,461 | $34K | |
| 85730 | <1% | 2,567 | $33K | |
| 74018 | <1% | 723 | $33K | |
| 83540 | <1% | 2,058 | $31K | |
| 82746 | <1% | 784 | $31K | |
| 82150 | <1% | 2,047 | $31K | |
| 87186 | <1% | 1,725 | $31K | |
| 86850 | <1% | 3,002 | $29K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,362 | $28K |
| 85610 | <1% | 4,199 | $27K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 922 | $27K |
| 86901 | <1% | 3,175 | $26K | |
| 86900 | <1% | 3,252 | $25K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 202 | $23K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 400 | $22K |
| 84439 | <1% | 870 | $21K | |
| 70486 | <1% | 81 | $21K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 29 | $20K |
| 80076 | <1% | 1,148 | $19K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 277 | $18K |
| 83550 | <1% | 964 | $18K | |
| 58558 | <1% | 16 | $17K | |
| 94761 | <1% | 306 | $17K | |
| 84100 | <1% | 1,727 | $17K | |
| 93270 | <1% | 543 | $16K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 639 | $16K |
| 88342 | <1% | 221 | $16K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,340 | $15K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 81 | $14K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,287 | $14K |
| 87486 | <1% | 294 | $14K | |
| 87581 | <1% | 273 | $13K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 108 | $13K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 997 | $13K |
| 97035 | <1% | 339 | $13K | |
| 86140 | <1% | 2,176 | $13K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 406 | $12K |
| 85652 | <1% | 1,488 | $12K | |
| 87070 | <1% | 787 | $12K | |
| 0100U | <1% | 215 | $12K | |
| 87076 | <1% | 1,733 | $11K | |
| 96367 | <1% | 200 | $11K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 52 | $11K |
| 85014 | <1% | 1,417 | $11K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,467 | $11K |
| 85018 | <1% | 1,421 | $11K | |
| 97014 | <1% | 186 | $10K | |
| 82803 | <1% | 398 | $9K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 275 | $9K |
| 97162 | <1% | 158 | $9K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,422 | $8K |
| 72100 | <1% | 164 | $8K | |
| 73090 | <1% | 206 | $8K | |
| 93925 | <1% | 59 | $8K | |
| 97161 | <1% | 187 | $8K | |
| 36600 | <1% | 475 | $7K | |
| 72050 | <1% | 118 | $7K | |
| 85378 | <1% | 579 | $7K | |
| 93880 | <1% | 67 | $6K | |
| 80074 | <1% | 126 | $6K | |
| 82570 | <1% | 438 | $6K | |
| 73080 | <1% | 116 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 35 | $6K |
| 84702 | <1% | 198 | $6K | |
| 20610 | <1% | 172 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,881 | $5K |
| 82652 | <1% | 207 | $5K | |
| 80069 | <1% | 193 | $5K | |
| 87522 | Neg quan hep c or qual rna | <1% | 174 | $5K |
| 76536 | <1% | 46 | $5K | |
| 85027 | <1% | 415 | $4K | |
| 85379 | <1% | 226 | $4K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 87 | $4K |
| 72128 | <1% | 12 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 473 | $4K |
| 12001 | <1% | 66 | $4K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 38 | $4K |
| 73502 | <1% | 111 | $4K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 32 | $4K |
| 90714 | <1% | 206 | $4K | |
| 59025 | Fetal non-stress test | <1% | 81 | $4K |
| J3490 | Unclassified drugs | <1% | 1,327 | $3K |
| 0012A | <1% | 258 | $3K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 91 | $3K |
| 93225 | <1% | 47 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 912 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,031 | $3K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 488 | $3K |
| 84436 | <1% | 100 | $3K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 340 | $3K |
| 88304 | <1% | 148 | $3K | |
| 87634 | <1% | 87 | $2K | |
| 90715 | <1% | 70 | $2K | |
| 74019 | <1% | 29 | $2K | |
| 93970 | <1% | 13 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 712 | $2K |
| 0001A | <1% | 267 | $2K | |
| 86038 | <1% | 102 | $2K | |
| 0011A | <1% | 301 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,235 | $2K |
| 73590 | <1% | 47 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 858 | $2K |
| 84550 | <1% | 193 | $2K | |
| 0002A | <1% | 133 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 343 | $2K |
| 81002 | <1% | 303 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 710 | $2K |
| 82248 | <1% | 88 | $1K | |
| 70220 | <1% | 21 | $1K | |
| 96368 | <1% | 34 | $1K | |
| 93226 | <1% | 16 | $1K | |
| 82977 | <1% | 89 | $1K | |
| 76775 | <1% | 15 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 30 | $1K |
| 82043 | <1% | 56 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,266 | $1K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 18 | $1K |
| 84481 | <1% | 27 | $992.68 | |
| 82140 | <1% | 59 | $936.52 | |
| 72070 | <1% | 15 | $915.10 | |
| 72040 | <1% | 14 | $911.93 | |
| 83615 | <1% | 90 | $909.73 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 192 | $906.69 |
| 76641 | <1% | 12 | $856.32 | |
| 86200 | <1% | 66 | $808.07 | |
| 80299 | <1% | 19 | $776.97 | |
| 72170 | <1% | 16 | $725.23 | |
| 80143 | <1% | 73 | $721.18 | |
| 83970 | <1% | 12 | $714.40 | |
| 84156 | <1% | 35 | $541.86 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 26 | $535.68 |
| 94760 | <1% | 51 | $530.99 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 31 | $487.77 |
| 84112 | <1% | 17 | $462.62 | |
| 82247 | <1% | 17 | $425.31 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 57 | $413.78 |
| 84146 | <1% | 13 | $403.18 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 178 | $381.96 |
| 86803 | <1% | 36 | $360.31 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 32 | $311.22 |
| 90686 | <1% | 26 | $306.88 | |
| 86756 | <1% | 54 | $303.47 | |
| 85384 | <1% | 30 | $281.88 | |
| 80164 | <1% | 31 | $267.09 | |
| 90662 | <1% | 14 | $236.64 | |
| 84132 | <1% | 56 | $235.62 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 39 | $205.49 |
| 99406 | <1% | 31 | $203.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $192.87 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $192.87 |
| 87205 | <1% | 15 | $188.56 | |
| 86431 | <1% | 26 | $169.99 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 12 | $157.10 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 106 | $154.07 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 138 | $151.43 |
| 99499 | <1% | 13 | $150.52 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 138 | $128.01 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 28 | $113.17 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 27 | $112.44 |
| 36416 | <1% | 33 | $97.74 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 17 | $88.16 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 26 | $81.52 |
| A9270 | Non-covered item or service | <1% | 156 | $79.30 |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 13 | $78.56 |
| 81003 | <1% | 17 | $72.30 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 115 | $66.50 |
| 80305 | <1% | 21 | $56.53 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 21 | $39.40 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12 | $14.99 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 31 | $0.03 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.